Sprint Bioscience AB is a Sweden-based drug development company. It is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The Company's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Companyâ€™s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
14/09/26	SEK 2.740	0.00%	153,490
11/09/26	SEK 2.740	0.00%	1,252,178
10/09/26	SEK 2.740	-4.86%	799,244
09/09/26	SEK 2.880	-9.72%	891,948
08/09/26	SEK 3.190	-1.54%	55,563

Delayed Quote Nasdaq Stockholm

More quotes

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 19:00:00 14/09/2026 +03			5-day change	1st Jan Change
2.740 ^SEK	0.00%		-15.43%	+86.39%

08-26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI

Market Cap	289M 29.6M 25.65M 24.21M 21.96M 41.2M 2.84B 41.5M 111M 1.44B 111M 109M 4.58B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	289M 29.6M 25.65M 24.21M 21.96M 41.2M 2.84B 41.5M 111M 1.44B 111M 109M 4.58B	EV / Sales 2026 *	3.33x	EV / Sales 2027 *	2.99x
Free-Float	72.16%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	SPRINT	Delayed
Deutsche Boerse AG	5JA1	Delayed
Börse Stuttgart	5JA1	Delayed
Boerse Muenchen	5JA1	Real-time

08-26	Sprint Bioscience AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Sprint Bioscience AB and Eli Lilly and Company Enter Agreement to Accelerate Drug Development	CI
06-26	Four stocks have so far today posted new 52-week highs on the Stockholm Stock Exchange	FW
06-18	Nine stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
06-16	Three stocks hit new 52-week highs on the Stockholm Stock Exchange today	FW
06-09	Calendar: Tuesday, June 9	FW
06-08	Calendar Tuesday June 9	FW
05-13	Sprint Bioscience Q1 operating loss SEK 14.3 mln	RE
05-13	Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-16	Sprint Bioscience completes strategic evaluation of STK25 program	RE
04-16	Sprint Bioscience and Experimental Drug Development Centre Complete Strategic STK25 Evaluation	CI
04-14	21 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW
04-10	15 stocks hit new 52-week highs on the Stockholm Stock Exchange so far today	FW

Sprint Bioscience AB Stock

Stocks

SPRINT

SE0006343745

Biotechnology & Medical Research

Valuation: Sprint Bioscience AB

Chart: Sprint Bioscience AB

Latest news: Sprint Bioscience AB

Analysts' recommendations: Sprint Bioscience AB

Press Releases: Sprint Bioscience AB

Quotes and Performance

Price Extremes

Managers and Directors: Sprint Bioscience AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Net sales - Rate of surprise

09-02	Sprint Bioscience (Q2 review): Continued positive progress	AQ
08-13	Sprint Bioscience's Upcoming Conferences and Investor Events	AQ
07-23	Sprint Bioscience announces agreement with Lilly TuneLab to accelerate drug development	AQ
06-04	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ
05-19	Sprint Bioscience (Q1 Review): Momentum in the business	AQ

1 week	-15.43%
Current month	-14.38%
1 month	-17.72%
3 months	-25.54%
6 months	+41.97%
Current year	+86.39%

1 week	2.55	3.14
1 month	2.55	3.47
Current year	1.36	4.59
1 year	0.51	4.59
3 years	0.36	4.59
5 years	0.36	5.4
10 years	0.36	40.9

Manager	Title	Age	Since
Johan Emilsson CEO	Chief Executive Officer	42	01/10/2023
Martin Andersson CTO	Chief Tech/Sci/R&D Officer	55	01/01/2009
Jenni Björnulfson DFI	Director of Finance/CFO	55	04/05/2026

Director	Title	Age	Since
Nils Rune Nordlander CHM	Chairman	70	01/01/2010
Fredrik Lehmann BRD	Director/Board Member	50	01/01/2019
Björn Magnus Sjöstrand CHM	Chairman	58	01/01/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SPRINT BIOSCIENCE AB	0.00%	-15.43%	+347.71%	+23.98%	29.6M
WUXI APPTEC CO., LTD.	+5.04%	+3.66%	+50.62%	+103.77%	70.24B
ARGENX SE	+1.64%	-0.18%	+34.67%	+76.81%	62.63B
INSMED INCORPORATED	-3.18%	-0.78%	-14.14%	+369.82%	27.36B
WUXI BIOLOGICS (CAYMAN) INC.	+0.61%	+0.32%	+27.34%	+12.67%	25.71B
BIONTECH SE	+2.20%	-4.72%	+2.19%	-13.14%	24.83B
GENMAB A/S	+1.15%	-1.17%	+17.56%	-21.92%	19.52B
PHARMAESSENTIA CORPORATION	-7.03%	-10.19%	+161.91%	+303.00%	15.51B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-4.24%	-5.78%	-9.67%	+482.03%	14.66B
SUMMIT THERAPEUTICS INC.	+4.96%	+4.63%	-2.75%	+864.40%	14.69B
Average	+0.10%	-3.19%	+61.55%	+220.14%	27.52B
Weighted average by Cap.	+1.32%	-0.81%	+31.90%	+168.10%

	2026 *	2027 *
Net sales	86.8M 8.89M 7.7M 7.27M 6.59M 12.37M 852M 12.46M 33.45M 432M 33.38M 32.65M 1.37B	96.8M 9.91M 8.59M 8.11M 7.35M 13.79M 950M 13.89M 37.3M 482M 37.23M 36.41M 1.53B
Net income	-	-
Net Debt	-	-